Cubist's Phase III Squaring Off Against Pain, Constipation
Cubist Pharmaceuticals Inc. followed up its earnings tally with word that the first patient joined the 1,800-patient Phase III program called ASCENT with bevenopran, previously known as CB-5945, a peripherally active mu opioid receptor antagonist for chronic noncancer pain and opioid-induced constipation.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter